Everything to Know about Macro and Markets Stocks clocked in their second consecutive weekly gain and the best start to a ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

The stocks listed here have all been struggling due to weak demand. They are cheap-looking buys that investors haven't been ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Business quiz! Shares of Meta Platforms touched a record high this week after: a) its megabillionaire chief executive Mark ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

If he’s confirmed as health secretary, Robert F. Kennedy Jr. will have broad authority to pursue an anti-vaccine agenda.